Microglia

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

Retrieved on: 
fredag, maj 31, 2024
Scientific Advisory Group, UPDATE, CHMP, GCP, Safety, ALS, Peripheral nervous system, Good, Masitinib, EMA, Euronext, Microglia, Science, Health Canada, AFL, EAE, Guideline, B cell, Quality of life, Central nervous system, Euronext Paris, Vaccine

SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS).
  • These issues and main justifications presented by AB Science are detailed in the presentation.
  • The EMA decision will be made public during the next CHMP meeting to be held on June 24-27, 2024.
  • AB Science has asked to Euronext Paris to resume listing of its shares from the opening of trading on Monday June 03, 2024.

Vigil Neuroscience to Present in Upcoming June Investor Conferences

Retrieved on: 
torsdag, maj 30, 2024
Conference, Microglia, Management

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.

Key Points: 
  • WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.
  • Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th at 9:30 a.m. E.T.
  • Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11th at 10:40 a.m. E.T.
  • The live webcasts from the events will be available on the Company’s website on the “Events & Presentations” page in the “Investors” section.

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
torsdag, maj 16, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, PET, Lung, Patient, Pharmacokinetics, RRMS, LPA1, Completion, Marketing, Food, J&J, University, Depression, IND, Therapy, Safety, Conference, Inflammation, Growth, Idiopathic pulmonary fibrosis, Research, IPO, Nomination, Davidson College, Microglia, Poster, Security, IPF, Pharmaceutical industry

In January 2024, Contineum nominated and began preclinical studies for CTX-343, a peripherally restricted (unable to cross the blood-brain-barrier) LPA1R antagonist.

Key Points: 
  • In January 2024, Contineum nominated and began preclinical studies for CTX-343, a peripherally restricted (unable to cross the blood-brain-barrier) LPA1R antagonist.
  • In March 2024, Contineum appointed commercial veteran Olivia Ware to its Board of Directors.
  • As of March 31, 2024, Contineum had cash, cash equivalents and marketable securities of $117.9 million, compared to $125.2 million at the end of 2023.
  • Research and development expenses were $7.8 million for the three months ended March 31, 2024, compared to $3.6 million for the three months ended March 31, 2024.

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

Retrieved on: 
onsdag, maj 8, 2024
Citizenship, Microglia, Conference, Webcast

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.

Key Points: 
  • WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.
  • To register for the live event, please click here .
  • The webcast will also be available on the Company’s website on the “Events & Presentations” page in the “Investors” section.
  • An archived webcast will be available for approximately 90 days following the presentation.

Alector Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
onsdag, maj 8, 2024
Alzheimer's disease, FDA, Brain, Total, Traffic barrier, ABC, Investment, Safety, AbbVie, Central nervous system disease, Alector, Arnon Rosenthal, ALEC, TREM2, Poster, Partnership, Microglia, CNS, Disease, Exercise, Therapy, Frontotemporal dementia, GSK, Patient, PROGRESS, BBB, Central nervous system, Drug development, PD, SAN, Strategic planning, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 2024, Alector’s cash, cash equivalents and investments totaled $562.1 million.

Key Points: 
  • We are excited to recognize the addition of Neil Berkley to our executive team as our Chief Business Officer.
  • Neil has over 20 years of corporate development, business development and strategic planning experience, spanning large pharma to small biotechs.
  • Alector will host a virtual research and development event on June 18, 2024, to discuss the company’s ABC technology platform.
  • Total research and development expenses for the quarter ended March 31, 2024, were $45.2 million, compared to $51.9 million for the quarter ended March 31, 2023.

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
tisdag, maj 7, 2024
American Academy, Research and development, IGNITE, Publication, Research, TREM2, Microglia, Administration, Patient, Enrollment, Interim, Clinical trial, Completeness, Pharmaceutical industry

WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress.

Key Points: 
  • In addition, two posters highlighting the ILLUMINATE Natural History Study of ALSP and the mechanism of action for iluzanebart were also presented.
  • Next data readout from Phase 2 IGNITE clinical trial on track for third quarter of 2024: The Company is on track to report additional data from its Phase 2 clinical trial evaluating iluzanebart in ALSP in the third quarter of 2024.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter ended March 31, 2024 were $14.3 million, compared to $13.8 million for the same period in 2023.
  • Net Loss: Loss from operations for the first quarter ended March 31, 2024 were $19.9 million, compared to $19.8 million for the same period in 2023.

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Retrieved on: 
tisdag, maj 7, 2024
Brain, ARCHER, Complement component 1q, CNV, Research, Microglia, Incidence, Patient, Eye, Pivotal, Vasculitis, Paratriathlon, Retinal pigment epithelium, Geographic atrophy, RPE, Atrophy, Annual general meeting, Synapse, ARVO, European Medicines Agency, Overalls, Visual acuity, Medical imaging

BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated antigen-binding fragment (Fab) designed to block C1q and activation of the classical complement cascade locally in the eye with an intravitreal formulation, and is the first therapeutic candidate for the treatment of GA to receive Priority Medicine (PRIME) designation by the European Medicines Agency. The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.

Key Points: 
  • The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.
  • “We are pleased to present additional clinical data from the ARCHER trial that are the first to show preservation of both vision and relevant anatomical structures following ANX007 treatment,” said Douglas Love, president and chief executive officer of Annexon.
  • “Importantly, the statistically significant preservation of photoreceptor anatomy measured by ellipsoid zone change highlights protection of key retinal structures associated with vision.
  • These two registrational trials are designed to confirm the Phase 2 ARCHER findings of protection against vision loss and underscore the unique neuroprotective mechanism of action of ANX007 and its competitive differentiation in visual function.

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
fredag, maj 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
torsdag, april 25, 2024
Political moderate, Inflammation, International, M1, WHO, Notifiable disease, USAN, Liver disease, Homeostasis, Chronic obstructive pulmonary disease, World Health Organization, Randomness, Monocyte, CVD, Drug development, Sepsis, DNA methylation, Microglia, Doctor of Philosophy, Dementia, Respiratory disease, Disease, IBD, INN, DNA, CKD, Exercise, Data, Inflammatory bowel disease, Diet, Patient, Macrophage, Metabolism, Cardiovascular disease, Jools' Annual Hootenanny, PD, Cancer, Chronic kidney disease, Gene, COPD, Vaccine

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters

Retrieved on: 
måndag, april 22, 2024
Immunosenescence, Neuroinflammation, Microglia, ACS Medicinal Chemistry Letters, Sympathetic nervous system, Therapy, Potassium, Frontotemporal dementia, Patient, ALS, KCNK13, Manuscript, Pharmaceutical industry

BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.

Key Points: 
  • BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
  • CVN293, currently in a Phase 1 study in healthy volunteers, targets the NETSseq-identified, potassium (K+) ion channel, KCNK13, which is specifically expressed in human microglia.
  • Elevated KCNK13 levels have been observed in post-mortem human brain tissue from individuals with Alzheimer’s disease and other neurodegenerative conditions.
  • “We are delighted to publish the discovery of CVN293 as we anticipate its ability to selectively suppress neuroinflammation while mitigating impacts on the peripheral immune system,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.